AELIS Share Price Performance
€1.56
-10.14 (-86.67%)
Price €1.56
Share Price€1.56
AELIS Community Narratives
There are no narratives available yet.
Recent AELIS News & Updates
No updates
Aelis Farma SA Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Sep 22, 2025
- Earnings per share (EPS)
- -0.55
- Gross Margin
- 100.00%
- Net Profit Margin
- -134.05%
- Debt/Equity Ratio
- 49.4%
Aelis Farma SA Competitors
About AELIS
- Founded
- 2013
- Employees
- 28
- CEO
- WebsiteView website
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
French Market Performance
- 7 Days: -2.6%
- 3 Months: -1.7%
- 1 Year: 5.2%
- Year to Date: 1.6%
Over the last 7 days, the market has dropped 2.6%, driven by a pullback of 8.0% in the Consumer Discretionary sector. In the last year, the market is actually up 5.2%. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading